FindTrial
Sign In

The Effects of dapagliflozin in patients with type 2 Diabetes in a rural hospital in South India

The cardiovascular, renal and metabolic effects of add-on therapy with dapagliflozin in patients with uncontrolled type 2 diabetes: an observational analytical study from a rural secondary hospital in South India.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/04/051669
Enrollment
110
Registered
2023-04-17
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications

Interventions

None listed

Sponsors

THE SCHIEFFELIN INSTITUTE OF HEALTH-RESEARCH AND LEPROSY CENTER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects should be at least 18 years of age Known to have T2DM for more than one year On Dapagliflozin for a minimum of 6 months

Exclusion criteria

Exclusion criteria: Gestational Diabetes

Design outcomes

Primary

MeasureTime frame
Blood Pressure – Systolic and Diastolic FBS, PPBS, HbA1C, LDL Timepoint: Baseline and 6 and 12 months—

Secondary

MeasureTime frame
Estimated Glomerular Filtration Rate, Creatinine Body weight Documented side effects of Dapagliflozin Timepoint: Baseline and 6 and 12 months—

Countries

India

Contacts

Public ContactRoopa B S

Department of Pharmacy Practice

roopasatyanarayan@gmail.com9047155003

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026